Cargando…

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries

BACKGROUND: A recently developed 10-valent pneumococcal non-typeable H influenzae protein D-conjugate vaccine (PHiD-CV) is expected to afford protection against more than two thirds of isolates causing IPD in children in Latin America, and also against acute otitis media caused by both Spn and NTHi....

Descripción completa

Detalles Bibliográficos
Autores principales:	Martí, Sebastián García, Colantonio, Lisandro, Bardach, Ariel, Galante, Julieta, Lopez, Analía, Caporale, Joaquín, Knerer, Gerhart, Gomez, Jorge Alberto, Augustovski, Federico, Pichon-Riviere, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766226/ https://www.ncbi.nlm.nih.gov/pubmed/24004943 http://dx.doi.org/10.1186/1478-7547-11-21

Ejemplares similares

Measuring the Benefits of Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions
por: Augustovski, Federico, et al.
Publicado: (2017)

Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina
por: Rubinstein, Adolfo, et al.
Publicado: (2010)

Development and application of a dynamic transmission model of health systems’ preparedness and response to COVID-19 in twenty-six Latin American and Caribbean countries
por: Santoro, Adrián, et al.
Publicado: (2022)

Optimizing Tobacco Advertising Bans in Seven Latin American Countries: Microsimulation Modeling of Health and Financial Impact to Inform Evidence-Based Policy
por: Bardach, Ariel, et al.
Publicado: (2021)

Health‐Related Quality of Life in Patients with Breast Cancer in Latin America and the Caribbean: A Systematic Review and Meta‐Analysis
por: Gonzalez, Lucas, et al.
Publicado: (2021)

Making visible the cost of informal caregivers’ time in Latin America: a case study for major cardiovascular, cancer and respiratory diseases in eight countries
por: Espinola, Natalia, et al.
Publicado: (2023)

Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model
por: Bardach, Ariel Esteban, et al.
Publicado: (2017)

Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru
por: Augustovski, Federico, et al.
Publicado: (2023)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
por: Southern, Jo, et al.
Publicado: (2018)

Publisher Correction: cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru
por: Augustovski, Federico, et al.
Publicado: (2023)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Invasive pneumococcal infection despite 7-valent conjugated vaccine
por: Joye, Sebastien, et al.
Publicado: (2013)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
por: Oligbu, Godwin
Publicado: (2020)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
por: Andrade, Ana Lucia, et al.
Publicado: (2014)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
por: Turner, Paul, et al.
Publicado: (2015)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi
por: Gordon, Stephen B., et al.
Publicado: (2003)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
por: ELEMRAID, M. A., et al.
Publicado: (2013)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
por: Biesbroek, Giske, et al.
Publicado: (2014)

Impact of 10-Valent Pneumococcal Conjugate Vaccine on Bacterial Meningitis in Madagascar
por: Andriatahirintsoa, Emilson Jean P R, et al.
Publicado: (2019)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
por: Levy, Corinne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9itcn1hc0g7825v8bf25qddsot